Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to -$19.0 million.

  • Altimmune's Net Income towards Common Stockholders rose 16.77% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 18.82%. This contributed to the annual value of -$95.1 million for FY2024, which is 7.53% down from last year.
  • Per Altimmune's latest filing, its Net Income towards Common Stockholders stood at -$19.0 million for Q3 2025, which was up 14.14% from -$22.1 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Net Income towards Common Stockholders peaked at -$14.9 million during Q1 2021, and registered a low of -$33.5 million during Q3 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$22.1 million (2025), whereas its average is -$22.2 million.
  • In the last 5 years, Altimmune's Net Income towards Common Stockholders crashed by 282.54% in 2021 and then rose by 29.83% in 2022.
  • Altimmune's Net Income towards Common Stockholders (Quarterly) stood at -$23.9 million in 2021, then increased by 9.33% to -$21.7 million in 2022, then plummeted by 46.08% to -$31.6 million in 2023, then grew by 26.37% to -$23.3 million in 2024, then grew by 16.77% to -$19.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$19.0 million for Q3 2025, versus -$22.1 million for Q2 2025 and -$19.6 million for Q1 2025.